Welcome to our dedicated page for Entasis Therapeutics Holdings news (Ticker: ETTX), a resource for investors and traders seeking the latest updates and insights on Entasis Therapeutics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entasis Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entasis Therapeutics Holdings's position in the market.
Entasis Therapeutics (NASDAQ: ETTX) has launched an expanded access program (EAP) for its investigational drug, sulbactam-durlobactam (SUL-DUR), targeting U.S. patients with serious Acinetobacter baumannii infections. This initiative provides pre-approval access to the drug for patients in critical need, aligning with the company's mission to help those without alternative treatment options. SUL-DUR is developed for tackling multidrug-resistant strains and is currently undergoing a Phase 3 clinical trial active in 17 countries.
Entasis Therapeutics Holdings announced that Dr. Manos Perros, CEO, will present at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be accessible on demand starting January 11 at 6:00 AM ET. Entasis focuses on developing antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, with candidates including sulbactam-durlobactam and zoliflodacin, among others. For more details, visit www.entasistx.com.
Entasis Therapeutics Holdings (NASDAQ: ETTX) announced participation in A.G.P.'s Virtual Healthcare Symposium on November 19, 2020. The event will feature 1-on-1 virtual investor meetings. Interested investors should contact their A.G.P. representative. Entasis is focused on developing novel antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria. Their pipeline includes candidates addressing Acinetobacter baumannii, Neisseria gonorrhoeae, Enterobacteriaceae, and Pseudomonas infections.
Entasis Therapeutics Holdings (ETTX) reported a net loss of $11.1 million for Q3 2020, significantly up from $3.5 million in Q3 2019. Research and development expenses also increased to $9.4 million, driven by spending on the SUL-DUR product candidate. Despite challenges posed by the COVID-19 pandemic, the company progressed in its Phase 3 clinical trials for Acinetobacter infections and gonorrhea, and closed a $25 million private placement to bolster its financial position. Cash reserves grew to $61.2 million, sufficient to fund operations into Q4 2021.
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) announced multiple data presentations at the virtual ID Week from October 21-25, 2020. Key presentations include:
- Sulbactam-durlobactam (ETX2514) effectiveness against multidrug-resistant Acinetobacter baumannii isolates from the Middle East.
- In vitro activity of ETX2514 against global Acinetobacter isolates.
- Retrospective review of serious infections caused by Acinetobacter baumannii.
- A novel β-lactamase inhibitor enhancing susceptibility against multidrug-resistant Mycobacterium abscessus.
All presentations are set for on-demand viewing on October 21.
Entasis Therapeutics Holdings (NASDAQ: ETTX) announced that CEO Dr. Manos Perros will present at multiple investment conferences in September 2020. These include the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, the Cantor 2020 Virtual Global Healthcare Conference on September 17, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22. A replay of the Cantor presentation will be accessible for 90 days after the event, and Dr. Perros will conduct one-on-one virtual meetings with investors interested in engaging with management.
Entasis Therapeutics (Nasdaq: ETTX) announced a definitive agreement to sell approximately $25 million in securities through a private placement with Innoviva and other institutional investors. The funds will support the ongoing ATTACK Phase 3 clinical trial for SUL-DUR, targeting infections caused by carbapenem-resistant Acinetobacter baumannii. The company plans to issue 9,345,794 units at $2.675 each, including common stock and warrants. The placement is set to close by September 1, 2020, pending customary conditions. A registration statement will be filed for resale of the securities.
Entasis Therapeutics Holdings (NASDAQ: ETTX) has secured an initial $3 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) with potential growth to $15.5 million. This funding supports the development of novel compounds from its non-β-lactam inhibitor (NBP) platform targeting drug-resistant infections such as Pseudomonas aeruginosa, E. coli, and Klebsiella. The partnership aims to advance candidates to IND-ready stage, validating the safety and efficacy of lead candidate ETX0462.
Entasis Therapeutics (NASDAQ: ETTX) has successfully closed the second tranche of a $35 million financing agreement with Innoviva (NASDAQ: INVA), providing approximately $31.7 million in gross proceeds. This financing will support the company's global Phase 3 ATTACK trial for its antibacterial candidate, sulbactam-durlobactam, targeting Acinetobacter infections. Following the agreement, Innoviva now holds 14 million shares and warrants, along with the right to appoint two directors to Entasis's board.
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) announced its Q1 2020 financial results, reporting a net loss of $15.3 million, up from $12.9 million YoY, attributed to increased R&D and administrative expenses. The company is advancing its antibacterial pipeline despite COVID-19 impacts on clinical trials. A private placement with Innoviva will raise approximately $35 million, supporting ongoing trials, including the ATTACK Phase 3 trial for SUL-DUR against Acinetobacter baumannii infections. Cash reserves stood at $27.5 million, providing runway into Q4 2020.
